ClinicalTrials.gg
CompletedNCT03055936COMDOS1Updated May 27, 2021Results posted

Dose-finding Pharmacokinetic Study in Healthy Males

A Phase 1 interventional study of Levodopa and Carbidopa in Healthy Volunteers, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Germany. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-27.

Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This is a phase I PK study in healthy males.

Read the detailed description

This is a phase I, open, repeated dose, randomised PK study in healthy males. The study will consist of 4 parallel groups (Groups 1-4). All groups will have a crossover design with 4 treatment periods, each lasting for 7 days.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written (IC) obtained.
  • Good general health ascertained by detailed medical history and physical examinations.
  • Males between 18-65 years of age inclusive at screening.
  • (BMI) between 19-30 kg/m2 (BMI = weight/height2) inclusive at screening.
  • Weight at least 55 kg inclusive at screening.
  • Regular intestinal transit (no recent history of recurrent constipation, diarrhoea, or other intestinal problems, and no history of major gastrointestinal surgery).
  • Subject with a partner of agrees to use adequate from the first dose of study treatment until 90 days after the last dose of study treatment. Adequate methods of contraception include: Hormonal contraceptives, barrier methods (condom, diaphragm, cervical cap, etc.) in combination with a spermicide, intrauterine device and sexual abstinence.
  • Subject agrees to not donate sperm from the first dose of study treatment until 90 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Evidence of cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic, endocrine, neurological or psychiatric disease or cancer (except local non-melanoma skin cancer) within the previous 2 years.
  • Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study. As an exception, paracetamol for occasional pain is allowed.
  • Any clinically significant abnormal laboratory value or (such as prolonged >450 ms or QRS >120 ms) that in the opinion of the investigator could interfere with the interpretation of study results or cause a health risk for the subject if he takes part in the study.
  • Known to the active substances or the of the drugs.
  • History of vasovagal collapses or vagal reactions with unexplained reason within the previous 2 years or a tendency for vasovagal reactions during blood sampling.
  • HR \< 50 bpm or > 90 bpm in the supine position after 5 min rest at the screening visit.
  • At the screening visit:

    • systolic BP \< 100 mmHg or > 140 mmHg in the supine position after 5 min rest
    • diastolic BP \< 50 mmHg or > 90 mmHg in the supine position after 5 min rest.
  • Creatinine > 1.5 x (ULN) and or aspartate aminotransferase >1.25 x ULN at screening.
  • History of anaphylactic/anaphylactoid reactions.
  • Strong tendency to motion sickness.
  • Recent or current (suspected) drug abuse.
  • Recent or current alcohol abuse; regular drinking of more than 21 units per week (1 unit = 4 cl spirits or equivalent).
  • Current use of nicotine-containing products more than 5 cigarettes (or equivalent)/day and/or inability to refrain from the use of nicotine-containing products for 48 h before the first dose in each period until collection of the 24 h PK sample in the morning of day 8.
  • Use of caffeine-containing beverages more than 600 mg of caffeine/day and/or inability to refrain from using caffeine-containing beverages 24 h before the first levodopa administration on the PK day (day 7) until collection of the 24 h PK sample in the morning of day 8.
  • Blood donation or loss of a significant amount of blood (> 500 ml) within 90 days before the first study treatment administration.
  • Participation in another drug study or administration of another investigational drug within 60 days before the first study treatment administration.
  • Veins unsuitable for repeated venipuncture or cannulation.
  • Predictable poor compliance or inability to communicate well with the study centre personnel.
  • Inability to participate in all treatment periods.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    A1

    levodopa 50 mg, carbidopa 12.5 mg

    Drug: Levodopa · Drug: Carbidopa

  • Experimental
    B1

    levodopa 50 mg, carbidopa 65 mg

    Drug: Levodopa · Drug: Carbidopa

  • Experimental
    C1

    levodopa 50 mg, carbidopa 65 mg, ODM-104 50 mg

    Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104

  • Experimental
    D1

    levodopa 50 mg, carbidopa 65 mg, ODM-104 100 mg A4 ; B4 l; C4 ; D4 levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg

    Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104

  • Experimental
    A2

    levodopa 100 mg, carbidopa 25 mg

    Drug: Levodopa · Drug: Carbidopa

  • Experimental
    B2

    levodopa 100 mg, carbidopa 65 mg

    Drug: Levodopa · Drug: Carbidopa

  • Experimental
    C2

    levodopa 100 mg, carbidopa 65 mg, ODM-104 50 mg

    Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104

  • Experimental
    D2

    levodopa 100 mg, carbidopa 37,5 mg

    Drug: Levodopa · Drug: Carbidopa

  • Experimental
    A3

    levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg

    Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104

  • Experimental
    B3

    levodopa 150 mg, carbidopa 65 mg

    Drug: Levodopa · Drug: Carbidopa

  • Experimental
    C3

    levodopa 150 mg, carbidopa 65 mg, ODM-104 50 mg

    Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104

  • Experimental
    D3

    levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg

    Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104

  • Experimental
    A4

    levodopa IR 100 mg (Sinemet), carbidopa 25 mg

    Drug: Levodopa · Drug: Carbidopa

  • Experimental
    B4

    levodopa 100 mg, carbidopa 65 mg

    Drug: Levodopa · Drug: Carbidopa

  • Experimental
    C4

    levodopa 100 mg, carbidopa 25 mg, ODM-104 100 mg

    Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104

  • Experimental
    D4

    levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg

    Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104

Interventions

  • Levodopa 50 mg or 100 mg or 150 mg

    Also known as: Sinemet

  • Carbidopa 12.5 mg or 25 mg or 65 mg

  • DrugODM-104

    ODM-104 50 mg or 100 mg

06

What researchers measure

Primary outcomes

  1. Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24)

    Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24)

    Time frame: During 24 hours

Secondary outcomes

  1. Fluctuation of Levodopa Cmax/Cmin, Tau

    Explore fluctuation of levodopa Cmax/Cmin, tau. Figures given are per performed statistical analysis.

    Time frame: 16 hours

  2. Levodopa Peak Plasma Concentration (Cmax)

    Levodopa peak plasma concentration (Cmax)

    Time frame: 24 hours

07

Results

Posted May 27, 2021

Participant flow

Participant flow — Overall Study
MilestoneGroup 1Group 2Group 3Group 4
Started14141414
Completed12131213
Not completed2121
Withdrew: Adverse event0111
Withdrew: Personal reason2010

Outcome measures

PrimaryLevodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24)

Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24)

Time frame:
During 24 hours
Reported as:
Mean · h*ng/ml
Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24)
h*ng/mlA1 50 mg LD + 12.5 mg CDB1 50 mg LD + 65 mg CDC1 50 mg LD + 65 mg CD + 50 mg ODM-104D1 50 mg LD + 65 mg CD + 100 mg ODM-104A2 100 mg LD + 25 mg CDB2 100 mg LD + 65 mg CDC2 100 mg of LD + 65 mg CD + 50 mg ODM-104D2 100 mg LD + 65 mg CD + 100 mg of ODM-104A3 150 mg LD + 37.5 mg CDB3 150 mg LD + 65 mg CDC3 150 mg LD + 65 mg CD + 50 mg ODM-104D3 150 mg LD + 65 mg CD + 100 mg ODM-104A4 (Sinemet) 100 mg IR LD + 25 mg CDB4 100 mg LD + 65 mg CDC4 100 mg LD + 25 mg CD + 100 mg ODM-104D4 100 mg LD + 65 mg CD + 100 mg ODM-104
Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24)4300 (3905 to 4734)5423 (4928 to 5968)7439 (6760 to 8186)9046 (8215 to 9960)9643 (9060 to 10263)10709 (10062 to 11399)15257 (14335 to 16239)17896 (16814 to 19048)14285 (13550 to 15061)15805 (14995 to 16658)22473 (21316 to 23693)25672 (24390 to 27021)7965 (6436 to 9859)8994 (7286 to 11104)13866 (11232 to 17118)16310 (13140 to 20246)
SecondaryFluctuation of Levodopa Cmax/Cmin, Tau

Explore fluctuation of levodopa Cmax/Cmin, tau. Figures given are per performed statistical analysis.

Time frame:
16 hours
Reported as:
Mean · (ng/ml)/(ng/ml)
Fluctuation of Levodopa Cmax/Cmin, Tau
(ng/ml)/(ng/ml)A1 50 mg LD + 12.5 mg CDB1 50 mg LD + 65 mg CDC1 50 mg LD + 65 mg CD + 50 mg ODM-104D1 50 mg LD + 65 mg CD + 100 mg ODM-104A2 100 mg LD + 25 mg CDB2 100 mg LD + 65 mg CDC2 100 mg of LD + 65 mg CD + 50 mg ODM-104D2 100 mg LD + 65 mg CD + 100 mg of ODM-104A3 150 mg LD + 37.5 mg CDB3 150 mg LD + 65 mg CDC3 150 mg LD + 65 mg CD + 50 mg ODM-104D3 150 mg LD + 65 mg CD + 100 mg ODM-104A4 (Sinemet) 100 mg IR LD + 25 mg CDB4 100 mg LD + 65 mg CDC4 100 mg LD + 25 mg CD + 100 mg ODM-104D4 100 mg LD + 65 mg CD + 100 mg ODM-104
Fluctuation of Levodopa Cmax/Cmin, Tau12.24 ± 5.737.49 ± 2.234.16 ± 0.773.02 ± 1.0011.00 ± 3.308.32 ± 2.234.46 ± 1.093.35 ± 0.748.45 ± 3.167.16 ± 3.873.67 ± 1.292.82 ± 0.9919.52 ± 14.139.18 ± 6.237.63 ± 12.963.04 ± 0.76
SecondaryLevodopa Peak Plasma Concentration (Cmax)

Levodopa peak plasma concentration (Cmax)

Time frame:
24 hours
Reported as:
Mean · ng/ml
Levodopa Peak Plasma Concentration (Cmax)
ng/mlA1 50 mg LD + 12.5 mg CDB1 50 mg LD + 65 mg CDC1 50 mg LD + 65 mg CD + 50 mg ODM-104D1 50 mg LD + 65 mg CD + 100 mg ODM-104A2 100 mg LD + 25 mg CDB2 100 mg LD + 65 mg CDC2 100 mg of LD + 65 mg CD + 50 mg ODM-104D2 100 mg LD + 65 mg CD + 100 mg of ODM-104A3 150 mg LD + 37.5 mg CDB3 150 mg LD + 65 mg CDC3 150 mg LD + 65 mg CD + 50 mg ODM-104D3 150 mg LD + 65 mg CD + 100 mg ODM-104A4 (Sinemet) 100 mg IR LD + 25 mg CDB4 100 mg LD + 65 mg CDC4 100 mg LD + 25 mg CD + 100 mg ODM-104D4 100 mg LD + 65 mg CD + 100 mg ODM-104
Levodopa Peak Plasma Concentration (Cmax)685.92 ± 193.08775.36 ± 186.29908.86 ± 230.23950.38 ± 241.601519.92 ± 294.511593.85 ± 288.951855.38 ± 240.581955.38 ± 278.622105.45 ± 422.052072.73 ± 403.782545.45 ± 424.302616.67 ± 388.761634.62 ± 361.701367.36 ± 352.261711.43 ± 316.101717.69 ± 641.60

Adverse events

Collected over Through study completion, upto 15 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A1 (Levodopa 50, Carbidopa 12.5)0/14 (0%)0/14 (0%)6/14 (42.9%)
B1 (Levodopa 50, Carbidopa 65)0/14 (0%)0/14 (0%)8/14 (57.1%)
C1 (Levodopa 50, Carbidopa 65, ODM-104 50)0/14 (0%)0/14 (0%)7/14 (50%)
D1 (Levodopa 50, Carbidopa 65, ODM-104 100)0/14 (0%)0/14 (0%)7/14 (50%)
A2 (levodopa100, Carbidopa 25)0/14 (0%)0/14 (0%)6/14 (42.9%)
B2 (Levodopa 100, Carbidopa 65)0/14 (0%)2/14 (14.3%)7/14 (50%)
C2 (levodopa100, Carbidopa 65, ODM-104 50)0/14 (0%)0/14 (0%)8/14 (57.1%)
D2 (Levodopa 100, Carbidopa 65, ODM-104 100)0/14 (0%)0/14 (0%)7/14 (50%)
A3 (Levodopa 150, Carbidopa 37.5)0/14 (0%)0/14 (0%)7/14 (50%)
B3 (Levodopa 150, Carbidopa 65)0/14 (0%)0/14 (0%)4/14 (28.6%)
C3 (Levodopa 150, Carbidopa 65, ODM-104 50)0/14 (0%)0/14 (0%)9/14 (64.3%)
D3 (Levodopa 150, Carbidopa 65, ODM-104 100)0/14 (0%)0/14 (0%)10/14 (71.4%)
A4 (Sinemet, Levodopa 100, Carbidopa 25)0/14 (0%)0/14 (0%)6/14 (42.9%)
B4 (Levodopa 100, Carbidopa 65)0/14 (0%)0/14 (0%)5/14 (35.7%)
C4 (Levodopa 100, Carbidopa 25, ODM-104 100)0/14 (0%)0/14 (0%)5/14 (35.7%)
D4 (Levodopa 100, Carbidopa 65, ODM-104 100)0/14 (0%)0/14 (0%)9/14 (64.3%)
Most frequent serious events
Most frequent serious events
EventA1 (Levodopa 50, Carbidopa 12.5)B1 (Levodopa 50, Carbidopa 65)C1 (Levodopa 50, Carbidopa 65, ODM-104 50)D1 (Levodopa 50, Carbidopa 65, ODM-104 100)A2 (levodopa100, Carbidopa 25)B2 (Levodopa 100, Carbidopa 65)C2 (levodopa100, Carbidopa 65, ODM-104 50)D2 (Levodopa 100, Carbidopa 65, ODM-104 100)A3 (Levodopa 150, Carbidopa 37.5)B3 (Levodopa 150, Carbidopa 65)C3 (Levodopa 150, Carbidopa 65, ODM-104 50)D3 (Levodopa 150, Carbidopa 65, ODM-104 100)A4 (Sinemet, Levodopa 100, Carbidopa 25)B4 (Levodopa 100, Carbidopa 65)C4 (Levodopa 100, Carbidopa 25, ODM-104 100)D4 (Levodopa 100, Carbidopa 65, ODM-104 100)
DiverticulitisReproductive system and breast disorders0/140/140/140/140/141/140/140/140/140/140/140/140/140/140/140/14
PeritonitisReproductive system and breast disorders0/140/140/140/140/141/140/140/140/140/140/140/140/140/140/140/14
Most frequent other events
Showing 10 of 60
Most frequent other events
EventA1 (Levodopa 50, Carbidopa 12.5)B1 (Levodopa 50, Carbidopa 65)C1 (Levodopa 50, Carbidopa 65, ODM-104 50)D1 (Levodopa 50, Carbidopa 65, ODM-104 100)A2 (levodopa100, Carbidopa 25)B2 (Levodopa 100, Carbidopa 65)C2 (levodopa100, Carbidopa 65, ODM-104 50)D2 (Levodopa 100, Carbidopa 65, ODM-104 100)A3 (Levodopa 150, Carbidopa 37.5)B3 (Levodopa 150, Carbidopa 65)C3 (Levodopa 150, Carbidopa 65, ODM-104 50)D3 (Levodopa 150, Carbidopa 65, ODM-104 100)A4 (Sinemet, Levodopa 100, Carbidopa 25)B4 (Levodopa 100, Carbidopa 65)C4 (Levodopa 100, Carbidopa 25, ODM-104 100)D4 (Levodopa 100, Carbidopa 65, ODM-104 100)
HeadacheNervous system disorders2/143/143/140/145/141/140/144/144/140/141/143/141/144/141/143/14
FatigueGeneral disorders1/145/140/140/141/141/142/142/140/140/140/141/140/140/141/140/14
DizzinessNervous system disorders3/141/140/141/140/142/141/141/140/140/141/140/142/140/140/140/14
DiarrhoeaGastrointestinal disorders3/142/141/140/140/142/140/141/141/140/140/142/140/140/142/140/14
NauseaGastrointestinal disorders0/140/140/143/140/141/140/141/141/142/142/142/141/140/142/141/14
RhinitisInfections and infestations0/143/140/140/140/140/141/142/140/140/140/140/142/141/140/142/14
Abdominal painGastrointestinal disorders1/143/141/140/140/140/140/142/140/140/140/141/140/140/141/140/14
Abdominal pain lowerGastrointestinal disorders1/140/140/140/140/141/140/142/140/140/140/140/140/140/140/140/14
FlatulenceGastrointestinal disorders1/140/141/140/140/140/142/142/142/141/142/142/141/141/141/141/14
EpistaxisRespiratory, thoracic and mediastinal disorders0/140/140/140/142/140/140/140/140/140/142/140/140/140/140/140/14

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group 1Group 2Group 3Group 4Total
<=18 years00000
Between 18 and 65 years1414141456
>=65 years00000
Age, Continuous
Age, Continuous(years)Group 1Group 2Group 3Group 4Total
Mean42.4 ± 13.749.5 ± 10.948.0 ± 13.546.0 ± 10.646.4 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Group 3Group 4Total
Female00000
Male1414141456
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Group 3Group 4Total
Female00000
Male1414141456
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1Group 2Group 3Group 4Total
American Indian or Alaska Native00000
Asian11114
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White1313131352
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Group 1Group 2Group 3Group 4Total
Germany1414141414
08

Study locations

1 site
  • Nuvisan Pharma Services
    Neu-Ulm, 89231, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Jun 2017, 3 months.

Results were first posted in May 2021, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2017
First posted
Feb 16, 2017
StartActual
Feb 21, 2017
Primary completionActual
Jun 9, 2017
CompletionActual
Jun 9, 2017
Results first posted
May 27, 2021
Last update
May 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03055936
Responsible party
Sponsor
First posted
Feb 16, 2017
Start date
Feb 21, 2017
Primary completion
Jun 9, 2017
Completion
Jun 9, 2017
Results posted
May 27, 2021
Last update
May 27, 2021

Study contacts

Denis Strugala, DR.med.
principal investigator · Nuvisan GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levodopa · Carbidopa

Start the discussion